leisure time -WSS

leisure time

author：explore 2025-10-01 18:32:24 - browse：71338

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Undocumented workers face uncertainty as immigration law takes effect in Florida

WSS

Dexcom's push to bring CGM to type 2 diabetes patients

Texas Medical Board asked to define abortion emergency exception

UpToDate has a racism problem: Dr. Stanley Goldfarb

Undocumented workers face uncertainty as immigration law takes effect in Florida

Readout Newsletter: Amgen, Regeneron, BGI Group and more

How Robert F. Kennedy Jr. distorted vaccine science

focus

leisure time

focus

At least 13 dead in Texas as scorching temps continue

Why Novartis is going to walk from its acquisition of MorphoSys

BioMarin wins approval for gene therapy to treat hemophilia A

The CDC's new social media misinformation war

George Santos makes 1st court appearance after pleading not guilty to 13 counts

340B reform proposal comes out of Senate working group

Anesthesiologist group: stop taking Ozempic before surgery

Use doctors trained outside the U.S. to ease the physician shortage

BioMarin wins approval for gene therapy to treat hemophilia A

340B reform proposal comes out of Senate working group

leisure time

Texas Medical Board asked to define abortion emergency exception

Top private equity targets in 2023: cardiology, clinical trials, lasers

Why Novartis is going to walk from its acquisition of MorphoSys

Lupron, used to halt puberty in children, may cause lasting health problems

STAT wants to know your pick for a great summer read or listen

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

knowledge

explore

hotspot

Wikipedia